RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME 04/16/2025 RECORDATI RARE DISEASES TO PRESENT NEW DATA IN CUSHING’S DISEASE AND CUSHING’S SYNDROME AT ENDO 2024 05/16/2024 RECORDATI RARE DISEASES ANNOUNCES THE CALL FOR APPLICATIONS TO THE ELEVENTH EDITION OF THE INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH ARRIGO RECORDATI 05/19/2023 Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next › Last page Last »
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME 04/16/2025
RECORDATI RARE DISEASES TO PRESENT NEW DATA IN CUSHING’S DISEASE AND CUSHING’S SYNDROME AT ENDO 2024 05/16/2024
RECORDATI RARE DISEASES ANNOUNCES THE CALL FOR APPLICATIONS TO THE ELEVENTH EDITION OF THE INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH ARRIGO RECORDATI 05/19/2023
